Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addictions and related disorders. News about Adial often centers on the progress of its lead investigational drug, AD04, a genetically targeted serotonin-3 receptor antagonist being developed for Alcohol Use Disorder (AUD) in heavy drinking patients with specific genotypes.
On this page, readers can find coverage of Adial’s clinical development milestones, including updates on the ONWARD™ pivotal Phase 3 trial and preparations for a new Phase 3 adaptive program informed by End of Phase 2 (EOP2) feedback from the U.S. Food and Drug Administration (FDA). Company announcements describe FDA recognition of AUD as an unmet need, support for Adial’s adaptive trial design, and confirmation of primary efficacy endpoints based on heavy drinking days.
Adial’s news flow also highlights its precision medicine strategy. Releases describe a partnership with Genomind to validate a cheek swab genetic test that identifies SNPs in serotonergic system genes such as HTR3A, HTR3B, and SLC6A4, enabling selection of biomarker-positive patients, including those with the AG+ genotype. Additional stories cover intellectual property developments, such as provisional and international patent applications for AD04 that the company expects, once granted, to protect core assets to at least 2045.
Investors and observers can also follow capital markets and listing-related updates, including public offerings of stock and warrants, at-the-market sales agreements, Nasdaq compliance notices, and extensions related to minimum bid price requirements. Together, these items provide context on how Adial is financing and structuring its efforts to advance AD04 and its broader addiction treatment pipeline. Bookmark this page to review new regulatory, clinical, financing, and intellectual property announcements as they are reported.
Adial Pharmaceuticals announced the issuance of patent number 11,351,154 on June 7, 2022, covering a genetic diagnostic panel linked to its lead product, AD04, aimed at treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). This patent enhances their intellectual property portfolio, now exceeding 90 patents worldwide, ensuring market protection until at least 2031. With an estimated 35 million individuals in the U.S. suffering from AUD, the company anticipates significant opportunities in both AD04 and its diagnostic test. Results from the pivotal ONWARD Phase 3 trial are expected soon.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a research collaboration between its subsidiary, Purnovate, and the Medical College of Wisconsin. The focus is on developing adenosine analogs as treatments for diabetes and non-alcoholic steatohepatitis (NASH). The collaboration aims to test Purnovate's compounds in preclinical models, which could potentially address significant unmet medical needs. The global NASH market is projected to exceed $54 billion by 2027, highlighting the potential market impact of these developments.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is nearing the completion of its ONWARD™ Phase 3 trial for AD04, aimed at treating Alcohol Use Disorder (AUD), with results expected this quarter. The company ended Q1 2022 with a cash balance of $12.7 million, up from $6.1 million in Q4 2021. R&D expenses dropped to $0.6 million, and net loss improved to $2.9 million. With AUD representing a $36 billion U.S. market and 35 million affected individuals, Adial plans to advance discussions for potential commercialization of AD04, which is designed for easy oral administration.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has announced a collaboration with UC San Diego to explore its adenosine analogs for treating inflammatory bowel disease (IBD). This partnership aims to validate the therapeutic potential of Purnovate’s compounds in preclinical models of IBD, conditions such as Crohn's disease, and ulcerative colitis. The global IBD treatment market is projected to reach USD 27.8 billion by 2028, indicating significant unmet medical needs. Adial's CEO expresses optimism about their compounds addressing IBD and other inflammatory conditions.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) will have CEO William Stilley participate in the 2022 Virtual Growth Conference from March 28-30. The event, hosted by Maxim Group LLC and M-Vest, requires prior membership to attend. Stilley's pre-recorded corporate update will be accessible throughout the conference. This event will feature presentations from various sectors, including Biotech and Healthcare. Adial is focused on developing treatments for addiction, with its lead drug AD04 currently in a pivotal Phase 3 trial for Alcohol Use Disorder.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the completion of patient enrollment in its ONWARD™ Phase 3 trial, focusing on AD04 for treating Alcohol Use Disorder (AUD). The trial included 302 participants across 25 sites in Europe, surpassing initial targets. The CEO highlighted the significance of this milestone, emphasizing the need for effective AUD treatments amid rising public health concerns. Topline results are expected in Q2, aiming to demonstrate a statistically significant reduction in heavy drinking days for those treated with AD04 compared to a placebo.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has successfully closed a registered direct offering, generating around $10 million. A single accredited institutional investor purchased approximately 2,322,250 shares of common stock, along with pre-funded warrants and additional warrants to acquire about 3,977,888 shares. The effective purchase price was $2.40 per share/warrant. The net proceeds will enhance Adial's balance sheet as it advances its Phase 3 ONWARD™ trial for AD04, targeting addiction treatments.
Adial Pharmaceuticals has entered into a securities purchase agreement with an institutional investor to raise approximately $10 million through a registered direct offering of common stock and related warrants. The agreement includes the sale of 4,187,250 shares at an effective purchase price of $2.40 per share, alongside warrants for 3,977,888 shares with an exercise price of $2.52. The closing date is anticipated on February 15, 2022, subject to customary conditions. The offering is being facilitated by Maxim Group LLC.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced promising results for its subsidiary, Purnovate's PNV-5032, in treating asthma. The in vivo study showed a 25% reduction in pulmonary flow resistance, which indicates improved airflow in an asthmatic model compared to controls. PNV-5032 exhibited over 1000-fold selectivity for the adenosine A1 receptor and demonstrated significantly higher solubility than similar compounds. The company aims to initiate first-in-human trials in 2023, supported by a patent application extending protection until 2047.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced that the U.S. Patent and Trademark Office has sent a Notice of Allowance for patent application No. 16/784,051 concerning the treatment of opioid use disorder (OUD) using its drug AD04. This application is particularly focused on patients with a genetic biomarker for the serotonin-3 receptor. Currently, AD04 is being evaluated in the ONWARD Phase 3 trial for alcohol use disorder (AUD). The company expects long-term patent protection through 2036, supporting its goal to address the significant market of OUD.